Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus

Molecular Carcinogenesis

Volumn 55, Issue 5, 2016, Pages 953-963

  Lieberman, Rachel ^a   Xiong, Donghai ^a   James, Michael ^a   Han, Younghun ^b   Amos, Christopher I ^b   Wang, Liang ^a   You, Ming ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cancer susceptibility gene; DNA damage; EQTL; Gene amplification; Lung cancer; Non small cell lung carcinoma; Senescence

Indexed keywords

RAD52 PROTEIN; RAD52 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BRONCHUS MUCOSA; CANCER RISK; CANCER SUSCEPTIBILITY; CELL AGING; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL LUNG CARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CAUCASIAN; CHROMOSOME 12; DNA DAMAGE; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; METABOLISM; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 12; DNA DAMAGE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN;

EID: 84930260740     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22334     Document Type: Article

References (24)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29.
2. Halmos B, Boiselle PM, Karp DD. Lung cancer. Prim Care Update Ob Gyns 2003; 10:87-94.
3. Shi J, Chatterjee N, Rotunno M, et al. Inherited variation at chromosome 12p13.33, including RAD52, influences the risk of squamous cell lung carcinoma. Cancer Discov 2012; 2:131-139.
4. Lisby M, Antunez de Mayolo A, Mortensen UH, Rothstein R. Cell cycle-regulated centers of DNA double-strand break repair. Cell Cycle 2003; 2:479-483.
5. Lisby M, Rothstein R, Mortensen UH. Rad52 forms DNA repair and recombination centers during S phase. Proc Natl Acad Sci USA 2001; 98:8276-8282.
6. Wang Y, McKay JD, Rafnar T, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet 2014; 46:736-741.
7. Lok BH, Powell SN. Molecular pathways: Understanding the role of Rad52 in homologous recombination for therapeutic advancement. Clin Cancer Res 2012; 18:6400-6406.
8. Feng Z, Scott SP, Bussen W, et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci USA 2011; 108:686-691.
9. Rijkers T, Van Den Ouweland J, Morolli B, et al. Targeted inactivation of mouse RAD52 reduces homologous recombination but not resistance to ionizing radiation. Mol Cell Biol 1998; 18:6423-6429.
10. Lok BH, Carley AC, Tchang B, Powell SN. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene 2013; 32:3552-3558.
11. Li Y, Sheu CC, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: A genome-wide association study. Lancet Oncol 2010; 11:321-330.
12. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012; 150:1121-1134.
13. McDoniels-Silvers AL, Herzog CR, Tyson FL, Malkinson AM, You M. Inactivation of both Rb and p53 pathways in mouse lung epithelial cell lines. Exp Lung Res 2001; 27:297-318.
14. Kim PM, Allen C, Wagener BM, Shen Z, Nickoloff JA. Overexpression of human RAD51 and RAD52 reduces double-strand break-induced homologous recombination in mammalian cells. Nucleic Acids Res 2001; 29:4352-4360.
15. Zhuang D, Mannava S, Grachtchouk V, et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 2008; 27:6623-6634.
16. Fragkos M, Jurvansuu J, Beard P. H2AX is required for cell cycle arrest via the p53/p21 pathway. Mol Cell Biol 2009; 29:2828-2840.
17. Franco S, Gostissa M, Zha S, et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell 2006; 21:201-214.
18. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 2003; 5:675-679.
19. Fernandez-Capetillo O, Chen HT, Celeste A, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 2002; 4:993-997.
20. Liu J, Heyer WD. Who's who in human recombination: BRCA2 and RAD52. Proc Natl Acad Sci USA 2011; 108:441-442.
21. Treuner K, Helton R, Barlow C. Loss of Rad52 partially rescues tumorigenesis and T-cell maturation in Atm-deficient mice. Oncogene 2004; 23:4655-4661.
22. Heyer WD, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. Annu Rev Genet 2010; 44:113-139.
23. Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006; 7:85-97.
24. MacLaren A, Black EJ, Clark W, Gillespie DA. C-Jun-deficient cells undergo premature senescence as a result of spontaneous DNA damage accumulation. Mol Cell Biol 2004; 24:9006-9018.